FDA Approves Truqap for PTEN-Deficient Prostate Cancer

1 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

Published
The FDA has approved an important new targeted treatment option for patients with advanced prostate cancer. In this episode of UroNurse News, host Vic Senese, RN, BSN, FAUNA, explains the latest approval of Truqap (capivasertib)in combination with hormonal therapy for patients with PTEN-deficient metastatic castration-resistant prostate cancer (mCRPC).

PTEN loss is one of the most common genetic alterations found in advanced prostate cancer and is associated with aggressive disease and poorer outcomes. This new FDA approval represents another step toward precision medicine by targeting the AKT signaling pathway, which becomes overactive when the PTEN tumor suppressor gene is lost.

In this episode, you'll learn:

What the FDA's new approval means for prostate cancer patients
What PTEN deficiency is and why it matters
How Truqap (capivasertib) works as an AKT inhibitor
Which patients may be eligible for this treatment
Clinical trial results that supported FDA approval
Expected benefits, progression-free survival data, and response rates
Common side effects and important monitoring considerations
How biomarker testing continues to shape personalized prostate cancer care
What oncology nurses, urology providers, patients, and caregivers should know
As precision medicine continues to evolve, molecular testing is becoming increasingly important in selecting the most effective treatments for advanced prostate cancer. Understanding biomarkers such as PTEN may help guide individualized treatment decisions and improve patient outcomes.

Whether you're a urology nurse, oncology nurse, advanced practice provider, physician, patient, caregiver, or healthcare professional interested in the latest advances in genitourinary oncology, this episode provides a concise overview of this significant FDA approval.

Categoria
Urology
Commenta per primo questo video.

Prossimo